BioCorteX, a London, UK-based digital medicine company that employs a first-principle computer simulation to understand drug-bacteria interactions and improve a person’s response to treatments, raised $5m in seed funding.
The round was led by Sofinnova Partners, and Hoxton Ventures. In conjunction with the funding, Edward Kliphuis, Partner at Sofinnova Partners, and Hussein Kanji, Partner, Hoxton Ventures, join the BioCorteX Board of Directors.
The company intends to use the funds to further develop its platform.
Led by Dr. Nik Sharma, Chief Executive Officer, and Dr. Mo Alomari, Chief Technology Officer, BioCorteX is developing precision medicine solutions using in silico simulation to solve the complex relationship bacteria, viruses and fungi play in health, disease and drug response. The company’s flagship product, Carbon Mirror™, uses technology incorporating principles of physics and chemistry to create in-silico simulations with high fidelity, to assess and predict an individual’s response to treatment based on their microbiome profile.
FinSMEs
31/03/2023